search
Back to results

Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement (VASCALB)

Primary Purpose

Blood Loss, Surgical, Fluid Retention

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Hyperoncotic Albumin 20%
Isooncotic Albumin 5%
Ringer's Lactate Crystalloid Solutions (control group)
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Blood Loss, Surgical focused on measuring hyperoncotic, isooncotic, albumin 20%, albumin 5%, ringer lactate, blood loss, hemorrhage, fluid replacement, intravascular effect, volume expansion, cystectomy, pro-ANP, pro-BNP, glycocalyx proteins, microcirculation damages, endothelial shedding, CD138/syndecan 1, heparan sulfate, hyaluronic acid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Non emergent radical cystectomy with urinary diversion
  • Adult: older than 18 years
  • Written informed consent

Exclusion Criteria:

  • Contraindications to the class of drugs under study (i.e: known hypersensitivity/ allergy to class of drugs or to the investigational product).
  • Renal insufficiency: GFR: <60ml/min/1.73m2 (KDIGO Clinical Practice Guideline for Acute Kidney Injury, stage 3 and over).
  • History of heart failure.
  • Use of diuretic treatment.
  • Women who are pregnant or breast feeding (exclusion of surgery per se).
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

Sites / Locations

  • Patrick Wuethrich, Department of Anaesthesiology and Pain Therapy, University Hospital Bern Inselspital Bern

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Albumin 20%

Albumin 5%

Ringer-lactate

Arm Description

3mL/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Outcomes

Primary Outcome Measures

Plasma volume expansion
Difference in plasma volume expansion of albumin 20%, albumin 5% and Ringer lactate calculated by volume kinetics

Secondary Outcome Measures

Biological markers (pro-ANP and pro-BNP)
Variation and comparison of kinetics hemodynamics biological markers such as pro-ANP and pro-BNP
Cardiac output (CO)
Evolution of cardiac output (CO) at the start of surgery, begin of infusion, stop of infusion and end of surgery.
Endothelial damage
Assessment of microcirculation damage due to peroperative stress and fluid therapy through Glycocalyx proteins (CD-138/syndecan 1, heparan sulfate and hyaluronic acid).
Stroke volume (SV)
Evolution of stroke volume at the start of surgery, begin of infusion, stop of infusion and end of surgery.
Pleth variability index (PVI)
Evolution of pleth variability index (PVI) at the start of surgery, begin of infusion, stop of infusion and end of surgery.

Full Information

First Posted
May 17, 2022
Last Updated
April 12, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT05391607
Brief Title
Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement
Acronym
VASCALB
Official Title
Randomized Trial of Intraoperative Intravascular Effect of Hyper-oncotic 20% Albumin, Iso-oncotic 5% Albumin and Ringer Lactate During Haemorrhage in Cystectomy. A Prospective Randomized Active-controlled Single Centre Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
May 25, 2022 (Actual)
Primary Completion Date
March 30, 2023 (Actual)
Study Completion Date
April 10, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Fluid intravascular replacement is usually performed with either balanced crystalloids or iso-oncotic colloids, (synthetic colloids, plasma and 5% albumin). Doubts have been raised about synthetic colloids, and albumin solutions have been used more extensively. Albumin is the main protein responsible for plasma oncotic pressure and its volume expansion effect. The mobilization of extravascular fluid by infusing a hyper-oncotic solution like 20% albumin solution has been shown, causing endogenous fluid recruitment and blood volume expansion. The primary objective of this study is to compare the effect on plasma volume expansion and fluid recruitment of 3 different types of fluids (Albumin 5% and Albumin 20% and Ringer-lactate) during the hemorrhagic phase of the cystectomy procedure. Secondary objectives are the assessment of the hemodynamic parameters during surgery and the follow-up of pro-ANP and pro-BNP peptides. Glycocalyx proteins will be followed to evaluate endothelial wall shedding and microcirculation damages.
Detailed Description
Bladder cancer occurs mainly in old comorbid patients. The standard treatment of localized muscle invasive bladder cancer is pelvic lymph node dissection and radical cystectomy with urinary diversion. Optimal perioperative fluid management for this surgery is challenging and still controversial in terms of how much to perfuse, choice of fluids to restore hydrated state and volemia. Fluid treatment is usually performed with either balanced crystalloids fluids or iso-oncotic synthetic colloids, or albumin 5%. Because crystalloids quickly equilibrate between the intravascular and interstitial volumes, they are mainly used to treat dehydration and temporary volume deficits. Doubts have been raised about synthetic colloids and the natural albumin has been used more extensively. Albumin is the main protein responsible for plasma oncotic pressure and its volume expansion effect. Iso-oncotic colloids (Albumine 5%) remain intravascular for a prolonged period, but they play a neutral role in terms of endogenous fluid recruitment, as the oncotic pressure is equilibrated between the intra- and extra- vascular territories. An alternative therapeutic option is the mobilization of tissue fluid by infusing a small amount of hyper-oncotic fluid like the albumin 20% solution, which has showed the advantage in its blood volume expansion capacities over crystalloids (endogenous fluid recruitment). The effects of the Albumin 20% solution have until now never been compared in a same perioperative setting to the Albumin 5% nor to Ringer-lactate solution. The investigators will evaluate the physiological effects and their outcomes between these fluid therapies in the frame of blood loss replacement during the hemorrhagic part of cystectomy procedures. The investigators will as well assess the variation of hemodynamic parameters (pro-ANP, pro-BNP) and the resulting microcirculation damages (endothelial wall shedding).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss, Surgical, Fluid Retention
Keywords
hyperoncotic, isooncotic, albumin 20%, albumin 5%, ringer lactate, blood loss, hemorrhage, fluid replacement, intravascular effect, volume expansion, cystectomy, pro-ANP, pro-BNP, glycocalyx proteins, microcirculation damages, endothelial shedding, CD138/syndecan 1, heparan sulfate, hyaluronic acid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Albumin 20%
Arm Type
Experimental
Arm Description
3mL/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Arm Title
Albumin 5%
Arm Type
Experimental
Arm Description
12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Arm Title
Ringer-lactate
Arm Type
Active Comparator
Arm Description
Ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Intervention Type
Drug
Intervention Name(s)
Hyperoncotic Albumin 20%
Other Intervention Name(s)
Albumin 20%
Intervention Description
Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Intervention Type
Drug
Intervention Name(s)
Isooncotic Albumin 5%
Other Intervention Name(s)
Albumin 5%
Intervention Description
Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Intervention Type
Drug
Intervention Name(s)
Ringer's Lactate Crystalloid Solutions (control group)
Other Intervention Name(s)
Ringer Lactate
Intervention Description
Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Primary Outcome Measure Information:
Title
Plasma volume expansion
Description
Difference in plasma volume expansion of albumin 20%, albumin 5% and Ringer lactate calculated by volume kinetics
Time Frame
5 hours
Secondary Outcome Measure Information:
Title
Biological markers (pro-ANP and pro-BNP)
Description
Variation and comparison of kinetics hemodynamics biological markers such as pro-ANP and pro-BNP
Time Frame
24 hours
Title
Cardiac output (CO)
Description
Evolution of cardiac output (CO) at the start of surgery, begin of infusion, stop of infusion and end of surgery.
Time Frame
5 hours
Title
Endothelial damage
Description
Assessment of microcirculation damage due to peroperative stress and fluid therapy through Glycocalyx proteins (CD-138/syndecan 1, heparan sulfate and hyaluronic acid).
Time Frame
24 hours
Title
Stroke volume (SV)
Description
Evolution of stroke volume at the start of surgery, begin of infusion, stop of infusion and end of surgery.
Time Frame
5 hours
Title
Pleth variability index (PVI)
Description
Evolution of pleth variability index (PVI) at the start of surgery, begin of infusion, stop of infusion and end of surgery.
Time Frame
5 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Non emergent radical cystectomy with urinary diversion Adult: older than 18 years Written informed consent Exclusion Criteria: Contraindications to the class of drugs under study (i.e: known hypersensitivity/ allergy to class of drugs or to the investigational product). Renal insufficiency: GFR: <60ml/min/1.73m2 (KDIGO Clinical Practice Guideline for Acute Kidney Injury, stage 3 and over). History of heart failure. Use of diuretic treatment. Women who are pregnant or breast feeding (exclusion of surgery per se). Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. Enrolment of the investigator, his/her family members, employees and other dependent persons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Y Wuethrich, MD
Organizational Affiliation
University Hospital Inselspital, Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Patrick Wuethrich, Department of Anaesthesiology and Pain Therapy, University Hospital Bern Inselspital Bern
City
Bern
State/Province
BE
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement

We'll reach out to this number within 24 hrs